Joseph P. Hagan becomes Chief Operating Officer at Regulus

He brings nearly 15 years of experience to the La Jolla, CA, US-based firm

Joseph Hagan will join Regulus Therapeutics, a California, US-based biopharmaceutical company developing medicines targeting microRNAs, on 4 January 2016.

Hagan has also been appointed Principal Financial Officer and Principal Accounting Officer.

He brings nearly 15 years of experience in leadership roles in business development and strategy in the biotechnology industry to the firm, having held positions at Orexigen Therapeutics and Amgen.

Hagan has led numerous strategic and financing transactions including the acquisitions of Immunex and Tularik and the spinout of Novantrone and Relyspa, as well as many other business development efforts.

Before joining Amgen, he spent five years in the bioengineering labs at Genzyme and Advanced Tissue Sciences. He is currently on the board of directors of Zosano Pharma, a publicly traded biotechnology company.

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Pharmaceutical

Therapeutic nucleotides: targeting genes

While very few nucleotide drugs have thus far reached the market, a huge amount of research is underway. Dr Sarah Houlton reports from the recent TIDES conference on a few nucleotide technologies with great therapeutic potential
Ingredients

Regulus and sanofi form microRNA therapeutics alliance

The deal represents the largest microRNA therapeutics alliance to date
Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Regulatory

Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China

The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
Manufacturing

Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company

The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
Subscribe now